Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Unlock the potential of using credit card points to book travel deals. Make the most of your rewards for a fantastic travel experience.
19,974 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Super Micro Computer reports revenue that more than doubles year over year, yet the shares sit flat as questions abou...
As volatility cools, the VIX holds near historically low levels while major indices chase new records. Earnings remai...
As 2026 unfolds, smart glasses are poised for a pivotal year, led by Meta and Google. Apple sits on the sidelines wit...
Howard Lindzon’s work with StockTwits and Social Leverage reshapes how we think about investing in communities. This ...
A new round of claims alleges harassment at Carta, the private equity software unicorn valued near $7.4 billion. As m...
Chip stocks pause after a blistering run, with Intel crashing 10%, slides as investors take profits and reassess AI m...
Solana surged 13% last week, its strongest performance of 2026, driven by ETF demand and higher futures activity. Tra...
Teva is shifting from a debt-laden generic player to a branded-focused pharma with a stronger balance sheet. This piv...
A World Economic Forum analysis shows women’s health receives only 20% of global R&D funding, leaving a $1 trillion o...
Independent single-family rental owners are largely insulated from institutional competition, according to TurboTenan...
Nvidia is poised to report fiscal Q1 2027 results as traders assess whether it can sustain a 75% gross margin amid re...